|
DETAILS
|
| COMPOSITION |
Each tablet contains Glimepiride 2 mg. |
| INDICATIONS |
Glimepiride monotherapy is indicated as an adjunct to diet and exercise for treatment of non-insulin dependent diabetes mellitus. It is also indicated for use in combination with insulin in patients with secondary failure. |
| MODE OF ACTION |
Glimepiride reduces blood glucose by stimulating insulin release from functioning pancreatic beta cells in response to glucose. At the cellular level, Glimepiride binds to a sulfonylurea receptor on the pancreatic beta-cell which inhibits the adenosine triphosphate-dependent potassium channel (K-ATP). Stabilization of potassium efflux causes depolarization and activation of the L-type calcium channel. Influx of calcium stimulates insulin secretion. |
| ONSET OF ACTION: |
2 to 4 hours |
| DURATION OF ACTION: |
24 hours |
| ADVERSE EFFECT: |
Adverse effects of glimepiride resemble those of other sulfonylureas, and include hypoglycemia, gastrointestinal symptoms, dizziness, headache, skin reactions, hyponatremia, and transaminase elevations |
| CONTRAINDICATION: |
Diabetic ketoacidosis , hypersensitivity to Sulfonylureas, pregnancy and lactation. |
| SPECIAL PRECAUTION: |
In the initial weeks of treatment the risk of hypoglycaemia may be increased and necessitates especially careful monitoring. Glucose levels in blood and urine must be checked regularly. Alertness and reactions may be impaired due to hypo or hyperglycaemia. This may affect the ability to operate a vehicle or heavy machinery. Dosage should be adjusted in patients with history of renal failure and hepatic insufficiency. Caution should be exercised while using in geriatric patients. |
| DRUG INTERACTION: |
Beta blocking agents appear to present minimal risk of altering glucose control in nondiabetic patients, although severe hypoglycemia has been reported in a nondiabetic patient receiving pindolol. The hypoglycemic action of sulfonylureas may be enhanced by chloramphenicol. Phenytoin may interact with glimepiride.
Disturbances of blood glucose including symptomatic hyper- and hypoglycemia may occur in patients treated concomitantly with gatifloxacin and levofloxacin. Both animal and human data suggest that ginseng may exert a significant hypoglycemic effect. Glucomannan may slow gastric emptying, increase the viscosity of gastrointestinal contents, and act as a barrier to diffusion, which slows absorption of hypoglycemic agents and glucose. Concomitant use of miconazole and oral hypoglycemic agents may lead to severe hypoglycemia. MAO inhibitors have been shown to cause excessive and prolonged hypoglycemia in some individuals. The manufacturers of some NSAIDs suggest that hypoglycemia may occur with coadministered sulfonylureas. The hypoglycemic action of sulfonylureas may be enhanced by probenecid. Increased risk of hypoglycemia when psyllium and antidiabetic agents are used together. |
| DOSAGE AND ADMINISTRATION: |
In patients with non-insulin-dependent (type II) diabetes mellitus, the recommended initial dose of glimepiride is 1 to 2 mg once daily, followed by gradual increases to a maximum of 8 mg once daily. Glimepiride 8 mg once daily may be combined with insulin in secondary failures. Glimepiride may also be used with metformin if glimepiride monotherapy does NOT achieve adequate lowering of blood glucose. |
| PACKING |
Strip of 10 tablets. |
Medicines for
Anti Diarrhoeal
Horn 
